{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-21-014888","form_type":"8-K","ticker":"CORT","cik":"0001088856","company_name":"CORCEPT THERAPEUTICS INC","filed_at":"2021-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.118939+00:00","generated_at":"2026-06-30T00:44:23.305622+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M","bullets":["Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.","Cash and investments $471.6M, +$16.8M from Q1; repurchased 1.4M shares for $30.8M.","2021 revenue guidance reaffirmed at $355-385M; CEO cites easing COVID restrictions driving growth.","Phase 3 pivotal trial of relacorilant in platinum-resistant ovarian cancer expected to start Q1 2022.","GRACE Phase 3 trial for relacorilant in Cushing's syndrome continues; NDA submission planned Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-21-014888","json":"https://secwatch.observer/filing/0001628280-21-014888.json","markdown":"https://secwatch.observer/filing/0001628280-21-014888.md","text":"https://secwatch.observer/filing/0001628280-21-014888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/0001628280-21-014888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/cort-20210729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:44:23.305622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}